Literature DB >> 21523301

Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study.

Éva A Enyedy1, Michael F Primik, Christian R Kowol, Vladimir B Arion, Tamás Kiss, Bernhard K Keppler.   

Abstract

Stoichiometry and stability of Ga(III), Fe(III), Fe(II) complexes of Triapine and five related α-N heterocyclic thiosemicarbazones with potential antitumor activity have been determined by pH-potentiometry, UV-vis spectrophotometry, (1)H NMR spectroscopy, and spectrofluorimetry in aqueous solution (with 30% DMSO), together with the characterization of the proton dissociation processes. Additionally, the redox properties of the iron complexes were studied by cyclic voltammetry at various pH values. Formation of high stability bis-ligand complexes was found in all cases, which are predominant at physiological pH with Fe(III)/Fe(II), whilst only at the acidic pH range with Ga(III). The results show that among the thiosemicarbazones with various substituents the N-terminal dimethylation does not exert a measurable effect on the redox potential, but has the highest impact on the stability of the complexes as well as the cytotoxicity, especially in the absence of a pyridine-NH(2) group in the molecule. In addition the fluorescence properties of the ligands in aqueous solution and their changes caused by Ga(III) were studied.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523301      PMCID: PMC3372890          DOI: 10.1039/c0dt01835j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  18 in total

1.  PH-metric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures.

Authors:  A Avdeef; K J Box; J E Comer; M Gilges; M Hadley; C Hibbert; W Patterson; K Y Tam
Journal:  J Pharm Biomed Anal       Date:  1999-08       Impact factor: 3.935

2.  Miniquad-A general computer programme for the computation of formation constants from potentiometric data.

Authors:  A Sabatini; A Vacca; P Gans
Journal:  Talanta       Date:  1974-01       Impact factor: 6.057

3.  Equilibrium and kinetic studies of iron(II) and iron(III) complexes of some alpha (N)-heterocyclic thiosemicarbazones. Reduction of the iron(III) complexes of 2-formylpyridine thiosemicarbazone and 2-acetylpyridine thiosemicarbazone by cellular thiol-like reducing agents.

Authors:  R H Borges; E Paniago; H Beraldo
Journal:  J Inorg Biochem       Date:  1997-03       Impact factor: 4.155

4.  Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.

Authors:  Shreelekha Adsule; Vivek Barve; Di Chen; Fakhara Ahmed; Q Ping Dou; Subhash Padhye; Fazlul H Sarkar
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

5.  Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase.

Authors:  Christian R Kowol; Roland Berger; Rene Eichinger; Alexander Roller; Michael A Jakupec; Peter P Schmidt; Vladimir B Arion; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

6.  Thermodynamics, kinetics, and mechanism of the stepwise dissociation and formation of Tris(L-lysinehydroxamato)iron(III) in aqueous acid.

Authors:  Joseph I Wirgau; Ivan Spasojević; Hakim Boukhalfa; Ines Batinić-Haberle; Alvin L Crumbliss
Journal:  Inorg Chem       Date:  2002-03-25       Impact factor: 5.165

7.  2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.

Authors:  Des R Richardson; Danuta S Kalinowski; Vera Richardson; Philip C Sharpe; David B Lovejoy; Mohammad Islam; Paul V Bernhardt
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

8.  Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex.

Authors:  Christian R Kowol; Robert Trondl; Vladimir B Arion; Michael A Jakupec; Irene Lichtscheidl; Bernhard K Keppler
Journal:  Dalton Trans       Date:  2009-10-22       Impact factor: 4.390

9.  Picoline-2-aldehyde thiosemicarbazone: The acid dissociation constants and reactions with various metals.

Authors:  D J Leggett; W A McBryde
Journal:  Talanta       Date:  1974-10       Impact factor: 6.057

10.  Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation.

Authors:  Christian R Kowol; Robert Trondl; Petra Heffeter; Vladimir B Arion; Michael A Jakupec; Alexander Roller; Mathea Sophia Galanski; Walter Berger; Bernhard K Keppler
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

View more
  17 in total

1.  Design and synthesis of novel N()-substituted thiosemicarbazones bearing a pyrrole unit as potential anticancer agents.

Authors:  Taofeng Zhu; Shanshan Shen; Qin Lu; Xingpei Ye; Weiliang Ding; Ruhua Chen; Jing Xie; Wenjiao Zhu; Jun Xu; Lei Jia; Weina Wu; Tieliang Ma
Journal:  Oncol Lett       Date:  2017-04-05       Impact factor: 2.967

2.  Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.

Authors:  Daniel Sun; Juno Van Valkenburgh; Sheba Plamthottam; Jeffrey Valenzuela; Bastian Ruehle; Dalton Steele; Soumya Poddar; Maxim Marshalik; Selena Hernandez; Caius Gabriel Radu; Jeffrey I Zink
Journal:  J Biol Inorg Chem       Date:  2019-06-27       Impact factor: 3.358

Review 3.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

4.  Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.

Authors:  Yimon Aye; Marcus J C Long; JoAnne Stubbe
Journal:  J Biol Chem       Date:  2012-08-22       Impact factor: 5.157

5.  Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.

Authors:  Caiguo Zhang; Guoqi Liu; Mingxia Huang
Journal:  Front Biol (Beijing)       Date:  2014-01-02

6.  Preparation, characterization, and anticancer efficacy of novel cobalt oxide nanoparticles conjugated with thiosemicarbazide.

Authors:  Mahsa Jarestan; Kimia Khalatbari; Ayda Pouraei; Seyed Ataollah Sadat Shandiz; Sadaf Beigi; Mohammad Hedayati; Amitis Majlesi; Fatemeh Akbari; Ali Salehzadeh
Journal:  3 Biotech       Date:  2020-05-05       Impact factor: 2.406

7.  Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.

Authors:  Ana Popović-Bijelić; Christian R Kowol; Maria E S Lind; Jinghui Luo; Fahmi Himo; Eva A Enyedy; Vladimir B Arion; Astrid Gräslund
Journal:  J Inorg Biochem       Date:  2011-07-31       Impact factor: 4.155

8.  A New Photoactivatable Ruthenium(II) Complex with an Asymmetric Bis-Thiocarbohydrazone: Chemical and Biological Investigations.

Authors:  Marianna Pioli; Nicolò Orsoni; Mirco Scaccaglia; Rossella Alinovi; Silvana Pinelli; Giorgio Pelosi; Franco Bisceglie
Journal:  Molecules       Date:  2021-02-10       Impact factor: 4.411

9.  Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones.

Authors:  Petra Heffeter; Christine Pirker; Christian R Kowol; Gerrit Herrman; Rita Dornetshuber; Walter Miklos; Ute Jungwirth; Gunda Koellensperger; Bernhard K Keppler; Walter Berger
Journal:  Biochem Pharmacol       Date:  2012-03-15       Impact factor: 5.858

10.  Synthesis, crystal structure and antiproliferative mechanisms of gallium(iii) complexes with benzoylpyridine thiosemicarbazones.

Authors:  Jinxu Qi; Taichen Liu; Wei Zhao; Xinhua Zheng; Yihong Wang
Journal:  RSC Adv       Date:  2020-05-18       Impact factor: 4.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.